Yanlong Shi

755 total citations
29 papers, 498 citations indexed

About

Yanlong Shi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yanlong Shi has authored 29 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Yanlong Shi's work include Ferroptosis and cancer prognosis (10 papers), RNA modifications and cancer (9 papers) and Cancer-related molecular mechanisms research (6 papers). Yanlong Shi is often cited by papers focused on Ferroptosis and cancer prognosis (10 papers), RNA modifications and cancer (9 papers) and Cancer-related molecular mechanisms research (6 papers). Yanlong Shi collaborates with scholars based in China, Israel and Japan. Yanlong Shi's co-authors include Tingting Shi, Shiwei Zhao, Yulin Liu, Yizhu Wang, Qiang Wang, Yewei Zhang, Wenning Zhang, Wei Qian, Zexuan Yan and Jingwang Bi and has published in prestigious journals such as Frontiers in Immunology, International Journal of Biological Macromolecules and Medicine.

In The Last Decade

Yanlong Shi

29 papers receiving 496 citations

Peers

Yanlong Shi
Mona Joudi Mashhad Iran
Fiona Maxwell United States
Lin Zhong China
Zhaoying Yang China
Daniela Frezzetti Italy
Haibo Lu China
Yi‐Fang Tsai Taiwan
Lanping Zhou China
Marina Sekacheva Russia
Mona Joudi Mashhad Iran
Yanlong Shi
Citations per year, relative to Yanlong Shi Yanlong Shi (= 1×) peers Mona Joudi Mashhad

Countries citing papers authored by Yanlong Shi

Since Specialization
Citations

This map shows the geographic impact of Yanlong Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanlong Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanlong Shi more than expected).

Fields of papers citing papers by Yanlong Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanlong Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanlong Shi. The network helps show where Yanlong Shi may publish in the future.

Co-authorship network of co-authors of Yanlong Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Yanlong Shi. A scholar is included among the top collaborators of Yanlong Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanlong Shi. Yanlong Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Yizhu, et al.. (2024). Ubiquitin specific peptidase 3: an emerging deubiquitinase that regulates physiology and diseases. Cell Death Discovery. 10(1). 243–243. 3 indexed citations
3.
Shi, Yanlong, et al.. (2024). How CLSPN could demystify its prognostic value and potential molecular mechanism for hepatocellular carcinoma: A crosstalk study. Computers in Biology and Medicine. 172. 108260–108260. 16 indexed citations
4.
Shi, Yanlong, et al.. (2024). A commentary on ‘Global trends in colorectal cancer and metabolic syndrome research: a bibliometric and visualization analysis’. International Journal of Surgery. 110(9). 5969–5970. 1 indexed citations
5.
Shi, Yanlong, et al.. (2023). Spotlights on ubiquitin-specific protease 12 (USP12) in diseases: from multifaceted roles to pathophysiological mechanisms. Journal of Translational Medicine. 21(1). 665–665. 6 indexed citations
6.
7.
Shi, Yanlong, et al.. (2023). N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. Frontiers in Endocrinology. 14. 1153802–1153802. 20 indexed citations
8.
Shi, Yanlong, Yizhu Wang, Wenning Zhang, et al.. (2023). Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy. APOPTOSIS. 28(9-10). 1423–1435. 41 indexed citations
9.
Jiang, Fei, Yanlong Shi, Yue Wang, et al.. (2023). Characterization of SHCBP1 to prognosis and immunological landscape in pan-cancer: novel insights to biomarker and therapeutic targets. Aging. 15(6). 2066–2081. 3 indexed citations
10.
Shi, Yanlong, Guo Huang, Fei Jiang, et al.. (2022). Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma. Frontiers in Immunology. 13. 1070593–1070593. 12 indexed citations
11.
Shi, Yanlong, et al.. (2022). A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. Hepatology International. 16(4). 906–917. 20 indexed citations
12.
13.
Zhu, Jun, Yanlong Shi, Jingsi Chen, et al.. (2022). Upregulated UBE4B expression correlates with poor prognosis and tumor immune infiltration in hepatocellular carcinoma. Aging. 14(23). 9632–9646. 6 indexed citations
14.
Shi, Yanlong, Yizhu Wang, Rui Yang, et al.. (2022). Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making. Frontiers in Endocrinology. 13. 1090324–1090324. 8 indexed citations
15.
Shi, Yanlong, Xinyu Ma, Menglu Wang, et al.. (2022). Comprehensive analyses reveal the carcinogenic and immunological roles of ANLN in human cancers. Cancer Cell International. 22(1). 188–188. 11 indexed citations
16.
Huang, Jin, et al.. (2020). A randomized controlled study for Yuanhu Zhitong dropping pills in the treatment of knee osteoarthritis. Medicine. 99(24). e20666–e20666. 4 indexed citations
17.
Li, Rui, et al.. (2018). NF-κB signaling and integrin-β1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis. International Journal of Biological Macromolecules. 123. 1035–1043. 44 indexed citations
18.
Wang, Qiang, Yanlong Shi, Kai Zhou, et al.. (2018). PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death and Disease. 9(7). 739–739. 108 indexed citations
19.
Shan, Fei, Yulin Liu, Qiang Wang, & Yanlong Shi. (2018). Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer. Oncology Letters. 16(3). 3274–3280. 15 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mona Joudi Mashhad Breakdown of academic impact, for papers by Fiona Maxwell Breakdown of academic impact, for papers by Lin Zhong Breakdown of academic impact, for papers by Zhaoying Yang Breakdown of academic impact, for papers by Daniela Frezzetti Breakdown of academic impact, for papers by Haibo Lu Breakdown of academic impact, for papers by Yi‐Fang Tsai Breakdown of academic impact, for papers by Lanping Zhou Breakdown of academic impact, for papers by Marina Sekacheva
Rankless by CCL
2026